Barbara Klajnert-Maculewicz

List of Publications by Year
in descending order

147 papers	6,789 citations	61687 45 h-index	84171 75 g-index
150 all docs	150 docs citations	150 times ranked	6931 citing authors

#	Article	IF	Citations
1	Triazineâ€"Carbosilane Dendrimersomes Enhance Cellular Uptake and Phototoxic Activity of Rose Bengal in Basal Cell Skin Carcinoma Cells. International Journal of Nanomedicine, 2022, Volume 17, 1139-1154.	3.3	7
2	The effect of surface modification of dendronized gold nanoparticles on activation and release of pyroptosis-inducing pro-inflammatory cytokines in presence of bacterial lipopolysaccharide in monocytes. Colloids and Surfaces B: Biointerfaces, 2022, 217, 112652.	2.5	3
3	Evaluation of dendronized gold nanoparticles as siRNAs carriers into cancer cells. Journal of Molecular Liquids, 2021, 324, 114726.	2.3	15
4	Systematic Studies of Gold Nanoparticles Functionalised with Thioglucose and its Cytotoxic Effect. ChemistrySelect, 2021, 6, 1230-1237.	0.7	1
5	Nanoparticles for Directed Immunomodulation: Mannose-Functionalized Glycodendrimers Induce Interleukin-8 in Myeloid Cell Lines. Biomacromolecules, 2021, 22, 3396-3407.	2.6	5
6	Star-Shaped Poly(furfuryl glycidyl ether)-Block-Poly(glyceryl glycerol ether) as an Efficient Agent for the Enhancement of Nifuratel Solubility and for the Formation of Injectable and Self-Healable Hydrogel Platforms for the Gynaecological Therapies. International Journal of Molecular Sciences, 2021, 22, 8386.	1.8	10
7	Noncovalent Interactions with PAMAM and PPI Dendrimers Promote the Cellular Uptake and Photodynamic Activity of Rose Bengal: The Role of the Dendrimer Structure. Journal of Medicinal Chemistry, 2021, 64, 15758-15771.	2.9	11
8	Synthesis and Shaping of Coreâ€"Shell Tecto Dendrimers for Biomedical Applications. Bioconjugate Chemistry, 2021, 32, 225-233.	1.8	11
9	Nanocarriers in photodynamic therapyâ€"in vitro and in vivo studies. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1509.	3.3	46
10	Application of new lysine-based peptide dendrimers D3K2 and D3G2 for gene delivery: Specific cytotoxicity to cancer cells and transfection in vitro. Bioorganic Chemistry, 2020, 95, 103504.	2.0	47
11	Synthesis, Internalization and Visualization of N-(4-Carbomethoxy) Pyrrolidone Terminated PAMAM [G5:G3-TREN] Tecto(dendrimers) in Mammalian Cells. Molecules, 2020, 25, 4406.	1.7	16
12	Hydrophilic Polyhedral Oligomeric Silsesquioxane, POSS(OH)32, as a Complexing Nanocarrier for Doxorubicin and Daunorubicin. Materials, 2020, 13, 5512.	1.3	3
13	Poly(lysine) Dendrimers Form Complexes with siRNA and Provide Its Efficient Uptake by Myeloid Cells: Model Studies for Therapeutic Nucleic Acid Delivery. International Journal of Molecular Sciences, 2020, 21, 3138.	1.8	38
14	In Search of a Phosphorus Dendrimer-Based Carrier of Rose Bengal: Tyramine Linker Limits Fluorescent and Phototoxic Properties of a Photosensitizer. International Journal of Molecular Sciences, 2020, 21, 4456.	1.8	13
15	Silver Nanoparticles Surface-Modified with Carbosilane Dendrons as Carriers of Anticancer siRNA. International Journal of Molecular Sciences, 2020, 21, 4647.	1.8	20
16	Glucose-modified carbosilane dendrimers: Interaction with model membranes and human serum albumin. International Journal of Pharmaceutics, 2020, 579, 119138.	2.6	8
17	Physicochemical and in vitro cytotoxicity studies of inclusion complex between gemcitabine and cucurbit[7]uril host. Bioorganic Chemistry, 2020, 99, 103843.	2.0	7
18	Influence of Free Fatty Acids on Lipid Membraneâ€"Nisin Interaction. Langmuir, 2020, 36, 13535-13544.	1.6	12

#	Article	IF	Citations
19	Sugar Modification Enhances Cytotoxic Activity of PAMAM-Doxorubicin Conjugate in Glucose-Deprived MCF-7 Cells â€“ Possible Role of GLUT1 Transporter. Pharmaceutical Research, 2019, 36, 140.	1.7	38
20	Cytotoxicity of Dendrimers. Biomolecules, 2019, 9, 330.	1.8	231
21	Pyrrolidone-modified PAMAM dendrimers enhance anti-inflammatory potential of indomethacin in vitro. Colloids and Surfaces B: Biointerfaces, 2019, 181, 959-962.	2.5	15
22	Non-Traditional Intrinsic Luminescence (NTIL): Dynamic Quenching Demonstrates the Presence of Two Distinct Fluorophore Types Associated with NTIL Behavior in Pyrrolidone-Terminated PAMAM Dendrimers. Journal of Physical Chemistry C, 2019, 123, 18007-18016.	1.5	28
23	Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy. Pharmaceutical Research, 2019, 36, 154.	1.7	54
24	Molecular Mechanisms of Antitumor Activity of PAMAM Dendrimer Conjugates with Anticancer Drugs and a Monoclonal Antibody. Polymers, 2019, 11, 1422.	2.0	11
25	Fludarabine-Specific Molecular Interactions with Maltose-Modified Poly(propyleneimine) Dendrimer Enable Effective Cell Entry of the Active Drug Form: Comparison with Clofarabine. Biomacromolecules, 2019, 20, 1429-1442.	2.6	16
26	Effect of the Structure of Therapeutic Adenosine Analogues on Stability and Surface Electrostatic Potential of their Complexes with Poly(propyleneimine) Dendrimers. Macromolecular Rapid Communications, 2019, 40, e1900181.	2.0	11
27	PAMAM and PPI Dendrimers in Biophysical and Thermodynamic Studies on the Delivery of Therapeutic Nucleotides, Nucleosides and Nucleobase Derivatives for Anticancer Applications. Series in Bioengineering, 2019, , 183-243.	0.3	2
28	Zwitterionic Gadolinium(III)-Complexed Dendrimer-Entrapped Gold Nanoparticles for Enhanced Computed Tomography/Magnetic Resonance Imaging of Lung Cancer Metastasis. ACS Applied Materials & Interfaces, 2019, 11, 15212-15221.	4.0	93
29	Gold Nanoparticles in Cancer Treatment. Molecular Pharmaceutics, 2019, 16, 1-23.	2.3	371
30	Non-traditional intrinsic luminescence: inexplicable blue fluorescence observed for dendrimers, macromolecules and small molecular structures lacking traditional/conventional luminophores. Progress in Polymer Science, 2019, 90, 35-117.	11.8	247
31	Poly(propyleneimine) glycodendrimers non-covalently bind ATP in a pH- and salt-dependent manner â€“ model studies for adenosine analogue drug delivery. International Journal of Pharmaceutics, 2018, 544, 83-90.	2.6	16
32	Pyrrolidone Modification Prevents PAMAM Dendrimers from Activation of Pro-Inflammatory Signaling Pathways in Human Monocytes. Molecular Pharmaceutics, 2018, 15, 12-20.	2.3	17
33	Glycodendrimer Nanocarriers for Direct Delivery of Fludarabine Triphosphate to Leukemic Cells: Improved Pharmacokinetics and Pharmacodynamics of Fludarabine. Biomacromolecules, 2018, 19, 531-543.	2.6	30
34	Terminal Sugar Moiety Determines Immunomodulatory Properties of Poly(propyleneimine) Glycodendrimers. Biomacromolecules, 2018, 19, 1562-1572.	2.6	10
35	Multivalent interacting glycodendrimer to prevent amyloid-peptide fibril formation induced by Cu(II): A multidisciplinary approach. Nano Research, 2018, 11, 1204-1226.	5.8	27
36	Conjugate of PAMAM Dendrimer, Doxorubicin and Monoclonal Antibodyâ€"Trastuzumab: The New Approach of a Well-Known Strategy. Polymers, 2018, 10, 187.	2.0	38

#	Article	IF	Citations
37	Complexes of Indomethacin with 4-Carbomethoxy-pyrrolidone PAMAM Dendrimers Show Improved Anti-inflammatory Properties and Temperature-Dependent Binding and Release Profile. Molecular Pharmaceutics, 2018, 15, 3573-3582.	2.3	15
38	Determination of non-traditional intrinsic fluorescence (NTIF) emission sites in 1-(4-carbomethoxypyrrolidone)-PAMAM dendrimers using CNDP-based quenching studies. Journal of Nanoparticle Research, 2018, 20, 1.	0.8	17
39	Intrinsic Fluorescence of PAMAM Dendrimersâ€"Quenching Studies. Polymers, 2018, 10, 540.	2.0	16
40	Dendrimers as nanocarriers for nucleoside analogues. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 114, 43-56.	2.0	24
41	Dendrimers for fluorescenceâ€based bioimaging. Journal of Chemical Technology and Biotechnology, 2017, 92, 1157-1166.	1.6	13
42	Mechanisms of Internalization of Maltose-Modified Poly(propyleneimine) Glycodendrimers into Leukemic Cell Lines. Biomacromolecules, 2017, 18, 1509-1520.	2.6	19
43	Binding of poly(amidoamine), carbosilane, phosphorus and hybrid dendrimers to thrombinâ€"Constants and mechanisms. Colloids and Surfaces B: Biointerfaces, 2017, 155, 11-16.	2.5	9
44	Cationic Phosphorus Dendrimer Enhances Photodynamic Activity of Rose Bengal against Basal Cell Carcinoma Cell Lines. Molecular Pharmaceutics, 2017, 14, 1821-1830.	2.3	24
45	Influence of core and maltose surface modification of PEIs on their interaction with plasma proteinsâ€"Human serum albumin and lysozyme. Colloids and Surfaces B: Biointerfaces, 2017, 152, 18-28.	2.5	10
46	Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups-its uptake, efflux, and location in a cell. Colloids and Surfaces B: Biointerfaces, 2017, 159, 211-216.	2.5	31
47	Sugar-Modified Poly(propylene imine) Dendrimers Stimulate the NF-Î°B Pathway in a Myeloid Cell Line. Pharmaceutical Research, 2017, 34, 136-147.	1.7	22
48	Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches. Progress in Polymer Science, 2017, 64, 23-51.	11.8	54
49	Unusual Enhancement of Doxorubicin Activity on Co-Delivery with Polyhedral Oligomeric Silsesquioxane (POSS). Materials, 2017, 10, 559.	1.3	11
50	Complexing Methylene Blue with Phosphorus Dendrimers to Increase Photodynamic Activity. Molecules, 2017, 22, 345.	1.7	15
51	Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17, 102-114.	0.9	9
52	Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance. International Journal of Pharmaceutics, 2016, 513, 572-583.	2.6	43
53	Two for the Price of One: PAMAM-Dendrimers with Mixed Phosphoryl Choline and Oligomeric Poly(Caprolactone) Surfaces. Bioconjugate Chemistry, 2016, 27, 1547-1557.	1.8	12
54	Fourier transform infrared spectroscopy (FTIR) characterization of the interaction of anti-cancer photosensitizers with dendrimers. Analytical and Bioanalytical Chemistry, 2016, 408, 535-544.	1.9	27

#	Article	IF	Citations
55	In Vitro Studies of Polyhedral Oligo Silsesquioxanes: Evidence for Their Low Cytotoxicity. Materials, 2015, 8, 6062-6070.	1.3	21
56	Cationic phosphorus dendrimers and therapy for Alzheimer's disease. New Journal of Chemistry, 2015, 39, 4852-4859.	1.4	43
57	Phosphorus dendrimers and photodynamic therapy. Spectroscopic studies on two dendrimer-photosensitizer complexes: Cationic phosphorus dendrimer with rose bengal and anionic phosphorus dendrimer with methylene blue. International Journal of Pharmaceutics, 2015, 492, 266-274.	2.6	34
58	Anticancer siRNA cocktails as a novel tool to treat cancer cells. Part (B). Efficiency of pharmacological action. International Journal of Pharmaceutics, 2015, 485, 288-294.	2.6	71
59	Maltose modified poly(propylene imine) dendrimers as potential carriers of nucleoside analog 5â€²-triphosphates.. International Journal of Pharmaceutics, 2015, 495, 940-947.	2.6	27
60	PAMAM dendrimer with 4-carbomethoxypyrrolidoneâ€"In vitro assessment of neurotoxicity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 409-411.	1.7	23
61	Dendritic glycopolymers based on dendritic polyamine scaffolds: view on their synthetic approaches, characteristics and potential for biomedical applications. Chemical Society Reviews, 2015, 44, 3968-3996.	18.7	114
62	Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report. Biomacromolecules, 2015, 16, 1-27.	2.6	117
63	A viologen phosphorus dendritic molecule as a carrier of ATP and Mant-ATP: spectrofluorimetric and NMR studies. New Journal of Chemistry, 2014, 38, 6212-6222.	1.4	10
64	How to study dendrimers and dendriplexes III. Biodistribution, pharmacokinetics and toxicity in vivo. Journal of Controlled Release, 2014, 181, 40-52.	4.8	93
65	Stabilizing effect of small concentrations of PAMAM dendrimers at the insulin aggregation. Colloids and Surfaces B: Biointerfaces, 2014, 116, 757-760.	2.5	20
66	Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer. International Journal of Pharmaceutics, 2014, 461, 391-402.	2.6	24
67	The antibacterial effect of the co-administration of poly(propylene imine) dendrimers and ciprofloxacin. New Journal of Chemistry, 2014, 38, 2987.	1.4	11
68	Interaction of cationic carbosilane dendrimers and their complexes with siRNA with erythrocytes and red blood cell ghosts. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 882-889.	1.4	23
69	Studying Complexes Between PPI Dendrimers and Mant-ATP. Journal of Fluorescence, 2013, 23, 349-356.	1.3	14
70	Contribution of hydrophobicity, DNA and proteins to the cytotoxicity of cationic PAMAM dendrimers. International Journal of Pharmaceutics, 2013, 454, 1-3.	2.6	18
71	Enhancement of antimicrobial activity by co-administration of poly(propylene imine) dendrimers and nadifloxacin. New Journal of Chemistry, 2013, 37, 4156.	1.4	18
72	Effect of viologenâ€"phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities. International Journal of Biological Macromolecules, 2013, 54, 119-124.	3.6	22

#	Article	IF	Citations
73	The influence of PAMAM dendrimers surface groups on their interaction with porcine pepsin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 1982-1987.	1.1	32
74	Modified PAMAM dendrimer with 4-carbomethoxypyrrolidone surface groups reveals negligible toxicity against three rodent cell-lines. Nanomedicine: Nanotechnology, Biology, and Medicine, 2013, 9, 461-464.	1.7	59
75	The Influence of Maltotriose-Modified Poly(propylene imine) Dendrimers on the Chronic Lymphocytic Leukemia Cells <i>in Vitro</i>: Dense Shell G4 PPI. Molecular Pharmaceutics, 2013, 10, 2490-2501.	2.3	32
76	Complexation of HIV derived peptides with carbosilane dendrimers. Colloids and Surfaces B: Biointerfaces, 2013, 101, 236-242.	2.5	40
77	Phosphorus Dendrimers as Carriers of siRNAâ€”Characterisation of Dendriplexes. Molecules, 2013, 18, 4451-4466.	1.7	40
78	Promising Low-Toxicity of Viologen-Phosphorus Dendrimers against Embryonic Mouse Hippocampal Cells. Molecules, 2013, 18, 12222-12240.	1.7	19
79	Highly Organized Self-Assembled Dendriplexes Based on Poly(propylene imine) Glycodendrimer and Anti-HIV Oligodeoxynucleotides. Current Medicinal Chemistry, 2012, 19, 4708-4719.	1.2	14
80	Kinetics of Amyloid and Prion Fibril Formation in the Absence and Presence of Dense Shell Sugar-Decorated Dendrimers. Current Medicinal Chemistry, 2012, 19, 5907-5921.	1.2	12
81	Carbosilane Dendrimers are a Non-Viral Delivery System for Antisense Oligonucleotides: Characterization of Dendriplexes. Journal of Biomedical Nanotechnology, 2012, 8, 57-73.	0.5	34
82	Cytotoxicity and Genotoxicity of Cationic Phosphorus-Containing Dendrimers. Current Medicinal Chemistry, 2012, 19, 6233-6240.	1.2	7
83	Dendrimers reduce toxicity of AÎ² 1-28 peptide during aggregation and accelerate fibril formation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 1372-1378.	1.7	49
84	Characteristics of complexes between poly(propylene imine) dendrimers and nucleotides. New Journal of Chemistry, 2012, 36, 1610.	1.4	14
85	Antimicrobial activity of poly(propylene imine) dendrimers. New Journal of Chemistry, 2012, 36, 2215.	1.4	46
86	siRNA carriers based on carbosilane dendrimers affect zeta potential and size of phospholipid vesicles. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2209-2216.	1.4	31
87	Cytotoxicity of PAMAM, PPI and maltose modified PPIdendrimers in Chinese hamster ovary (CHO) and human ovarian carcinoma (SKOV3) cells. New Journal of Chemistry, 2012, 36, 428-437.	1.4	61
88	The biodistribution of maltotriose modified poly(propylene imine) (PPI) dendrimers conjugated with fluoresceinâ€”proofs of crossing bloodâ€“brainâ€“barrier. New Journal of Chemistry, 2012, 36, 350-353.	1.4	48
89	Biological Properties of New Viologen-Phosphorus Dendrimers. Molecular Pharmaceutics, 2012, 9, 448-457.	2.3	85
90	Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity. Biochemical and Biophysical Research Communications, 2012, 427, 197-201.	1.0	20

#	Article	IF	Citations
91	Surface modification of PAMAM dendrimer improves its biocompatibility. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 815-817.	1.7	96
92	Impact of maltose modified poly(propylene imine) dendrimers on liver alcohol dehydrogenase (LADH) internal dynamics and structure. New Journal of Chemistry, 2012, 36, 1992.	1.4	8
93	Stability of Dendriplexes Formed by Anti-HIV Genetic Material and Poly(propylene imine) Dendrimers in the Presence of Glucosaminoglycans. Journal of Physical Chemistry B, 2012, 116, 14525-14532.	1.2	11
94	Modulation of biogenic amines content by poly(propylene imine) dendrimers in rats. Journal of Physiology and Biochemistry, 2012, 68, 447-454.	1.3	9
95	Molecular Properties of Lysine Dendrimers and their Interactions with Aβ-Peptides and Neuronal Cells. Current Medicinal Chemistry, 2012, 20, 134-143.	1.2	53
96	Influence of dendrimers on red blood cells. Cellular and Molecular Biology Letters, 2012, 17, 21-35.	2.7	50
97	Phosphorus Dendrimers Affect Alzheimerâ€™s (AÎ²_{1â€“28}) Peptide and MAP-Tau Protein Aggregation. Molecular Pharmaceutics, 2012, 9, 458-469.	2.3	98
98	Influence of fourth generation poly(propyleneimine) dendrimers on blood cells. Journal of Biomedical Materials Research - Part A, 2012, 100A, 2870-2880.	2.1	54
99	Genotoxicity of poly(propylene imine) dendrimers. Biopolymers, 2012, 97, 642-648.	1.2	32
100	Effect of phosphorus dendrimers on DMPC lipid membranes. Chemistry and Physics of Lipids, 2012, 165, 408-413.	1.5	35
101	Cationic carbosilane dendrimersâ€“lipid membrane interactions. Chemistry and Physics of Lipids, 2012, 165, 401-407.	1.5	30
102	The influence of maltose modified poly(propylene imine) dendrimers on hen egg white lysozyme structure and thermal stability. Colloids and Surfaces B: Biointerfaces, 2012, 95, 103-108.	2.5	35
103	Dendrimers in Photodynamic Therapy. Current Medicinal Chemistry, 2012, 19, 4903-4912.	1.2	41
104	Cytotoxicity and Genotoxicity of Cationic Phosphorus-Containing Dendrimers. Current Medicinal Chemistry, 2012, 19, 6233-6240.	1.2	18
105	Cytotoxicity and genotoxicity of cationic phosphorus-containing dendrimers. Current Medicinal Chemistry, 2012, 19, 6233-40.	1.2	4
106	Interactions of phosphorus-containing dendrimers with liposomes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2011, 1811, 221-226.	1.2	40
107	The influence of PAMAM-OH dendrimers on the activity of human erythrocytes ATPases. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2714-2723.	1.4	28
108	Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity. Neuroscience, 2011, 180, 229-237.	1.1	49

#	Article	IF	Citations
109	<i>In vivo</i> toxicity of poly(propyleneimine) dendrimers. Journal of Biomedical Materials Research - Part A, 2011, 99A, 261-268.	2.1	96
110	Interaction of cationic phosphorus dendrimers (CPD) with charged and neutral lipid membranes. Colloids and Surfaces B: Biointerfaces, 2011, 82, 8-12.	2.5	41
111	Characterization of complexes formed by polypropylene imine dendrimers and anti-HIV oligonucleotides. Colloids and Surfaces B: Biointerfaces, 2011, 83, 360-366.	2.5	33
112	Time Evolution of the Aggregation Process of Peptides Involved in Neurodegenerative Diseases and Preventing Aggregation Effect of Phosphorus Dendrimers Studied by EPR. Biomacromolecules, 2010, 11, 3014-3021.	2.6	35
113	Effect of amyloid beta peptides Aî²1â€"28 and Aî²25â€"40 on model lipid membranes. Journal of Thermal Analysis and Calorimetry, 2010, 99, 741-747.	2.0	30
114	Metabolic limitations of the use of nucleoside analogs in cancer therapy may be overcome by application of nanoparticles as drug carriers: A review. Drug Development Research, 2010, 71, 383-394.	1.4	6
115	New Drug Delivery Nanosystem Combining Liposomal and Dendrimeric Technology (Liposomal) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	47
116	Influence of Surface Functionality of Poly(propylene imine) Dendrimers on Protease Resistance and Propagation of the Scrapie Prion Protein. Biomacromolecules, 2010, 11, 1314-1325.	2.6	81
117	Haemolytic activity of polyamidoamine dendrimers and the protective role of humanÂserum albumin. Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences, 2010, 466, 1527-1534.	1.0	35
118	Binding Properties of Water-Soluble Carbosilane Dendrimers. Journal of Fluorescence, 2009, 19, 267-275.	1.3	21
119	Dendrimers in gene transfection. Biochemistry (Moscow), 2009, 74, 1070-1079.	0.7	50
120	Interactions between dendrimers and heparin and their implications for the anti-prion activity of dendrimers. New Journal of Chemistry, 2009, 33, 1087.	1.4	50
121	The Influence of Densely Organized Maltose Shells on the Biological Properties of Poly(propylene) Tj ETQq1 1 0.784314 rgBT /Overlock 14, 7030-7041.	1.7	135
122	Analysis of Interaction between Dendriplexes and Bovine Serum Albumin. Biomacromolecules, 2007, 8, 2059-2062.	2.6	47
123	Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185â€"208. Biochemical and Biophysical Research Communications, 2007, 364, 20-25.	1.0	65
124	Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins. Organic and Biomolecular Chemistry, 2007, 5, 1886-1893.	1.5	55
125	Binding properties of polyamidoamine dendrimers. Journal of Applied Polymer Science, 2007, 103, 2036-2040.	1.3	21
126	EPR Study of the Interactions between Dendrimers and Peptides Involved in Alzheimer's and Prion Diseases. Macromolecular Bioscience, 2007, 7, 1065-1074.	2.1	81

#	Article	IF	Citations
127	Interactions between PAMAM dendrimers and gallic acid molecules studied by spectrofluorimetric methods. Bioelectrochemistry, 2007, 70, 50-52.	2.4	11
128	Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimerâ€™s and prion diseases. Biochemical and Biophysical Research Communications, 2006, 339, 577-582.	1.0	108
129	Influence of dendrimerâ€™s structure on its activity against amyloid fibril formation. Biochemical and Biophysical Research Communications, 2006, 345, 21-28.	1.0	159
130	Dendrimerâ€"protein interactions studied by tryptophan room temperature phosphorescence. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2006, 1764, 1750-1756.	1.1	38
131	Cytotoxicity, haematotoxicity and genotoxicity of high molecular mass arborescent polyoxyethylene polymers with polyglycidol-block-containing shells. Cell Biology International, 2006, 30, 248-252.	1.4	33
132	Biological properties of low molecular mass peptide dendrimers. International Journal of Pharmaceutics, 2006, 309, 208-217.	2.6	67
133	DSC studies on interactions between low molecular mass peptide dendrimers and model lipid membranes. International Journal of Pharmaceutics, 2006, 327, 145-152.	2.6	49
134	Effect of dendrimers on pure acetylcholinesterase activity and structure. Bioelectrochemistry, 2006, 68, 56-59.	2.4	45
135	Molecular Interactions of Dendrimers with Amyloid Peptides:â€‰ pH Dependence. Biomacromolecules, 2006, 7, 2186-2191.	2.6	83
136	Use of a Spectrofluorimetric Method to Monitor Changes of Human Serum Albumin Thermal Stability in the Presence of Polyamidoamine Dendrimers. Journal of Fluorescence, 2006, 16, 149-152.	1.3	16
137	PAMAM dendrimers and model membranes: Differential scanning calorimetry studies. International Journal of Pharmaceutics, 2005, 305, 154-166.	2.6	57
138	Dendrimer Interactions with Hydrophobic Fluorescent Probes and Human Serum Albumin. Journal of Fluorescence, 2005, 15, 21-28.	1.3	61
139	The effect of PAMAM dendrimers on human and bovine serum albumin at different pH and NaCl concentrations. Journal of Biomaterials Science, Polymer Edition, 2005, 16, 1081-1093.	1.9	37
140	Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry, 2004, 63, 189-191.	2.4	140
141	Incorporation of fluorescent probes into PAMAM dendrimers. Bioelectrochemistry, 2004, 63, 193-197.	2.4	19
142	The effect of polyamidoamine dendrimers on human erythrocyte membrane acetylcholinesterase activity. Bioelectrochemistry, 2004, 65, 23-26.	2.4	51
143	Estimation of PAMAM Dendrimers' Binding Capacity by Fluorescent Probe ANS. Journal of Fluorescence, 2003, 13, 519-524.	1.3	29
144	Interactions between PAMAM dendrimers and bovine serum albumin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1648, 115-126.	1.1	199

#	Article	IF	Citations
145	Fluorescence studies on PAMAM dendrimers interactions with bovine serum albumin. Bioelectrochemistry, 2002, 55, 33-35.	2.4	258
146	Dendrimers: properties and applications.. Acta Biochimica Polonica, 2001, 48, 199-208.	0.3	404
147	Dendrimers: properties and applications. Acta Biochimica Polonica, 2001, 48, 199-208.	0.3	53